Poor
Not Aligned
Patient Risk:
High
Summary
Multiple statements are not supported by the provided FDA label excerpts (e.g., antidepressant/other anti-seizure/topical and non-label switching/selection criteria). Only a small subset of claims aligns with the label (e.g., neuropathic pain indication and renal dose adjustment; tapering on discontinuation).
Category Scores
Accurate Statements
Pregabalin is used for neuropathic (nerve) pain.
1 INDICATIONS AND USAGE (neuropathic pain associated with diabetic peripheral neuropathy; postherpetic neuralgia)
If pregabalin is being discontinued, clinicians usually taper rather than stop abruptly to lower withdrawal risk.
5.6 Risks Associated with Abrupt or Rapid Discontinuation (taper gradually over minimum of 1 week)
Pregabalin dosing is affected by renal function.
2.5 Patients with Renal Impairment (adjust dose based on CLcr)
Unsupported Statements
Pregabalin is used for fibromyalgia.
Label excerpt states efficacy has not been established for fibromyalgia with pregabalin extended-release tablets.
Gabapentin is another alpha-2-delta calcium channel drug used for neuropathic pain.
Provided label excerpt (12.1) explains pregabalin mechanism; it does not support gabapentin being described as an alpha-2-delta calcium channel drug or that it is used for neuropathic pain.
Clinicians may switch from pregabalin to other medicines that target similar pain pathways.
No provided label support for switching to other medicines based on 'similar pain pathways.'
Certain antidepressants are used for neuropathic pain.
No provided label support for antidepressant use for neuropathic pain.
Certain antidepressants used for neuropathic pain may include serotonin-norepinephrine reuptake inhibitors or tricyclic-type agents.
No provided label support for these specific antidepressant classes in neuropathic pain.
Certain anti-seizure medicines other than pregabalin can be used for nerve pain.
No provided label support for using other anti-seizure medicines for nerve pain.
Topical options can be used for localized neuropathic pain when appropriate.
No provided label support for topical options.
Drug choice for pregabalin alternatives depends on side-effect tolerance.
No provided label support for 'alternative' selection criteria.
Drug choice for pregabalin alternatives depends on kidney function.
Label supports pregabalin dose adjustment in renal impairment, not selection of pregabalin alternatives.
Drug choice for pregabalin alternatives depends on age.
Label excerpt on geriatric use does not provide alternative drug selection guidance by age.
Drug choice for pregabalin alternatives depends on whether the person is already taking other sedating medications.
Label excerpt discusses additive CNS depressant effects for pregabalin, not alternative selection rules.
Gabapentin can replace pregabalin.
Label excerpt provided under drug interactions does not support a substitution/replacement claim.
Switching from pregabalin to gabapentin usually involves cross-titration.
Provided conversion table is for switching between pregabalin formulations (LYRICA to pregabalin extended-release), not for switching to gabapentin.
Switching from pregabalin requires careful monitoring for dizziness.
Label excerpt supports pregabalin-related dizziness/somnolence generally; it does not specifically support monitoring advice tied to 'switching to other drugs.'
Switching from pregabalin requires careful monitoring for sleepiness.
Same issue: label excerpt supports pregabalin dizziness/somnolence generally; not specific to switching.
Switching from pregabalin requires careful monitoring for balance issues.
No provided label support for balance-issue monitoring specifically.
Some antidepressants are used specifically for neuropathic pain even when a person is not being treated for depression.
No provided label support.
Antidepressants may be considered for neuropathic pain when pregabalin causes unwanted effects.
Label excerpt does not support antidepressant substitution for pregabalin adverse effects.
Antidepressants may be considered when pain persists despite treatment.
No provided label support.
The choice of antidepressant for neuropathic pain depends on heart rhythm risk.
No provided label support.
The choice of antidepressant for neuropathic pain depends on drug interactions.
No provided label support.
The choice of antidepressant for neuropathic pain depends on sleep effects.
No provided label support.
The choice of antidepressant for neuropathic pain depends on other conditions.
No provided label support.
Other anti-seizure medicines can sometimes be used for neuropathic pain when pregabalin fails or causes side effects.
No provided label support.
Selection of other anti-seizure medicines for neuropathic pain depends on efficacy for the specific pain syndrome.
No provided label support for selecting other anti-seizure medicines for neuropathic pain.
Selection of other anti-seizure medicines for neuropathic pain depends on tolerability, including sedation/edema/dizziness.
No provided label support for selection rules for other anti-seizure medicines; label excerpts for sedation/edema/dizziness are about pregabalin.
Non-oral options for pregabalin can be considered for some localized nerve-pain conditions.
No provided label support for non-oral options or localized nerve-pain indications.
Topical therapies may reduce systemic side effects.
No provided label support.
Topical therapies are typically used for specific syndromes and areas of pain rather than for generalized neuropathic pain.
No provided label support.
Patients often seek alternatives to reduce drowsiness/dizziness/balance problems/blurred thinking/impaired coordination/withdrawal or rebound symptoms/weight gain/swelling.
Label excerpt supports adverse reactions (e.g., dizziness/somnolence, weight gain, peripheral edema, discontinuation symptoms) but does not support claims about patient-seeking frequency or such qualitative 'often' statements.
The best pregabalin alternative depends on diagnosis.
No provided label support for selecting 'pregabalin alternatives.'
The best pregabalin alternative depends on other medicines, especially other sedatives or alcohol.
Label excerpt discusses pregabalin CNS effects with other CNS depressants; it does not provide alternative-selection guidance.
The best pregabalin alternative depends on sleep factors/mood factors/history of falls or gait instability/prior response and side effects.
No provided label support for alternative-selection criteria.
Pregabalin is widely available as a generic in many markets.
No provided label support; this is a non-label market/availability claim.
DrugPatentWatch.com tracks information related to drug-specific patent and exclusivity questions.
Irrelevant to the supplied label excerpts.
Contradictions
High
AI Statement
Pregabalin is used for fibromyalgia.
Label Reference
1 INDICATIONS AND USAGE (Efficacy ... has not been established for the management of fibromyalgia...)
Important Omissions
Boxed warning and contraindications evaluation (not included in provided label excerpts).
Importance:
Moderate
Broader dosing/administration safety details beyond renal impairment and discontinuation tapering (e.g., other dose initiation/maintenance specifics) were not assessed against the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
At least one direct contraindication-type risk is not evaluated, but there is a high-impact contradiction (fibromyalgia efficacy claim). Several other statements could mislead selection/switching decisions (antidepressants/other anti-seizure/topical and cross-titration/substitution claims) without label support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple critical claims are unsupported by the provided FDA label excerpts, including a fibromyalgia indication contradiction and numerous speculative switching/alternative-selection/substitution statements.
Suggested Improvement
Restrict claims to what is explicitly supported by the supplied label excerpts (indications: diabetic peripheral neuropathy and postherpetic neuralgia; renal impairment dosing; tapering on discontinuation; pregabalin-related dizziness/somnolence and peripheral edema/weight gain). Remove or qualify any statements about antidepressants, other anti-seizure drugs, topical/non-oral options, and switching/cross-titration/substitution criteria unless the exact FDA label text supports them.